What is the recommended adult dose of bleomycin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bleomycin Dosing for Adults

The standard adult dose of bleomycin is 0.25 to 0.50 units/kg (10 to 20 units/m²) administered intravenously, intramuscularly, or subcutaneously, given weekly or twice weekly 1.

Standard Dosing by Indication

Germ Cell Tumors, Squamous Cell Carcinoma, and Non-Hodgkin's Lymphoma

  • Dose: 0.25 to 0.50 units/kg (10 to 20 units/m²)
  • Route: IV, IM, or SC
  • Frequency: Weekly or twice weekly 1

Hodgkin's Disease

  • Initial dose: 0.25 to 0.50 units/kg (10 to 20 units/m²) weekly or twice weekly
  • Maintenance dose: After 50% response, reduce to 1 unit daily or 5 units weekly IV or IM 1

Malignant Pleural Effusion

  • Dose: 60 units as a single-dose bolus
  • Route: Intrapleural injection 1

Critical Dosing Considerations

Test Dosing for Lymphoma Patients

Lymphoma patients must receive a test dose of 2 units or less for the first 2 doses due to anaphylactoid reaction risk. Only proceed with regular dosing if no acute reaction occurs 1.

Cumulative Dose Limits

Total cumulative doses exceeding 400 units should be given with extreme caution due to dramatically increased pulmonary toxicity risk 1. The UK guideline recommends post-treatment CT scanning for all patients receiving more than 300 units 2.

Renal Dose Adjustments

For creatinine clearance (CrCl) < 50 mL/min, reduce doses as follows 1:

  • CrCl 40-50 mL/min: 70% of standard dose
  • CrCl 30-40 mL/min: 60% of standard dose
  • CrCl 20-30 mL/min: 55% of standard dose
  • CrCl 10-20 mL/min: 45% of standard dose
  • CrCl 5-10 mL/min: 40% of standard dose

Administration Methods

Route Flexibility

There is no evidence supporting superiority of bolus versus continuous infusion 2. The TE-3 trial found no difference in CT-assessed lung toxicity between 72-hour continuous infusion versus daily bolus 2.

Typical administration schedules involve weekly bleomycin as an IV bolus or short infusion 2. In UK practice, 68% of clinicians use IV infusion (ranging 30 minutes to 18 hours), 26% use IV bolus, and 6% use IM injection 2.

IV Administration Specifics

  • Dissolve 15-unit vial in 5 mL of 0.9% sodium chloride
  • Dissolve 30-unit vial in 10 mL of 0.9% sodium chloride
  • Administer slowly over 10 minutes 1

Monitoring Requirements

Symptom Surveillance

Use a toxicity checklist before and after every cycle 2. Cough is the most sensitive symptom for predicting pulmonary toxicity—development of new cough should trigger immediate HRCT imaging 2.

Renal Function

Check renal function prior to every cycle 2.

Post-Treatment Imaging

All patients receiving >300 units should receive post-treatment CT scan 2.

Key Safety Warnings

Pulmonary toxicity increases dramatically above 400 units total dose 1. When bleomycin is combined with other antineoplastic agents, pulmonary toxicity may occur at lower cumulative doses 1.

Patients over age 40 have twofold increased risk of pulmonary toxicity and should receive baseline CT thorax before starting bleomycin 2.

If new respiratory symptoms develop, omitting the next dose is safer than risking exacerbation of toxicity—continuation decisions should always be made at consultant level 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.